Kehao Zhu

zhukehao@uw.edu
telephone: (206)-734-7978

EDUCATION

University of Washington — Seattle, WA
Ph.D. in Biostatistics — 2020–2024 (expected)
- Dissertation: Statistical Methods for Risk Prediction, Cancer Screening, and Sequential Decision
- Committee: Yingye Zheng; Gary Chan; Yingqi Zhao; Ruth Etzioni; Riki Peters

University of Washington — Seattle, WA
M.S. in Biostatistics — 2014–2016

Purdue University — West Lafayette, IN
B.S. in Statistics & Biology — 2011–2014

China Agricultural University — Beijing, China
a joint B.S. in Biology — 2009–2014

EXPERIENCE

Fred Hutchinson Cancer Center — Seattle, WA
Statistical Research Associate II ⇒ III ⇒ Graduate Research Assistant — 2019–current
- Collaborative work with Canary Prostate Cancer Active Surveillance Study (PASS) on cancer biomarkers and epidemiological studies
- Methodological research on absolute risk prediction, cancer screening and sequential decisions

Axio Research LLC (now part of Cytel Inc) — Seattle, WA
Biostatistician ⇒ Senior Biostatistician ⇒ Principal Biostatistician — 2016–2019
- Provided statistical, interim report programming and project management support to Data Monitoring Committees (DMCs) of industry-sponsored clinical trials

University of Washington — Seattle, WA
Graduate Research Assistant — 2014–2016
- Statistical research on precision medicine
- Data management and consulting

Purdue University — West Lafayette, IN
Research Assistant — 2012–2014
- Predicting 30-day hospital readmission risk

SCHOLARSHIPS

- Society for Clinical Trials (SCT) Thomas C. Chalmers Student Scholarship Finalist — 2024
- JSM Student Paper Award of ASA Risk Analysis Section — 2024
- ENAR Distinguished Student Paper Award — 2024
- FDA-ASA Oncology Educational Fellowship — 2024
- Travel grant to a modeling workshop at Statistical and Applied Mathematical Sciences Institute (SAMSI) — 2013
- Fesenmyer Scholarship, Purdue University — 2012
- Discovery Park Undergraduate Research Scholarship, Purdue University — 2012 –2014

Publications and Manuscripts

[1] **K. Zhu**, K. C. G. Chan, and Y. Zheng, "Two-step error-controlling classifiers", *in preparation*, 2024+.

[2] **K. Zhu**, Y. Zhao, and Y. Zheng, "Designing cancer screening trials for the late-stage cancer incidence reduction", *revision invited at Biometrics*, 2024+.

[3] **K. Zhu**, Y. Zheng, and K. C. G. Chan, "Weighted brier score - an overall summary measure with clinical utility consideration", *submitted*, 2024+.

[4] J. M. Schenk, M. Liu, M. L. Neuhouser, L. F. Newcomb, Y. Zheng, **K. Zhu**, J. D. Brooks, P. R. Carroll, A. Dash, W. J. Ellis, *et al.*, "Dietary patterns and risk of gleason grade progression among men on active surveillance for prostate cancer: Results from the canary prostate active surveillance study", *Nutrition and Cancer*, vol. 75, no. 2, pp. 618–626, 2023.

[5] L. Brady, L. F. Newcomb, **K. Zhu**, Y. Zheng, H. Boyer, N. D. Sarkar, J. K. McKenney, J. D. Brooks, P. R. Carroll, A. Dash, *et al.*, "Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance", *Cancer Medicine*, vol. 11, no. 22, pp. 4332–4340, 2022.

[6] C. P. Filson, **K. Zhu**, Y. Huang, Y. Zheng, L. F. Newcomb, S. Williams, J. D. Brooks, P. R. Carroll, A. Dash, W. J. Ellis, *et al.*, "Impact of prostate health index results for prediction of biopsy grade reclassification during active surveillance", *The Journal of urology*, vol. 208, no. 5, pp. 1037–1045, 2022.

[7] P. S. Kirk, **K. Zhu**, Y. Zheng, L. F. Newcomb, J. M. Schenk, J. D. Brooks, P. R. Carroll, A. Dash, W. J. Ellis, C. P. Filson, *et al.*, "Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer", *Cancer*, vol. 128, no. 2, pp. 269–274, 2022.

[8] A. J. Waisman Malaret, P. Chang, **K. Zhu**, Y. Zheng, L. F. Newcomb, M. Liu, J. K. McKenney, J. D. Brooks, P. Carroll, A. Dash, *et al.*, "Evaluating the outcomes of active surveillance in grade group 2 prostate cancer: Prospective results from the canary pass cohort", *The Journal of urology*, vol. 207, no. 4, pp. 805–813, 2022.

[9] J. Schenk, L. Newcomb, Y. Zheng, A. Faino, **Zhu, K**, Y. Nyame, J. Brooks, P. Carroll, M. Cooperberg, A. Dash, *et al.*, "Re: African american race is not associated with risk of reclassification during active surveillance: Results from canary prostate cancer active surveillance study reply", *The Journal of urology*, vol. 205, no. 2, pp. 339–340, 2021.

[10] A. J. Waisman Malaret, P. Chang, L. Newcomb, A. Faino, Y. Zheng, **Zhu, Kehao**, J. K. McKenney, J. D. Brooks, A. Dash, W. J. Ellis, *et al.*, "Effect of diagnostic biopsy practice location on grade/volume reclassification in active surveillance for prostate cancer: A multicenter analysis from the canary pass cohort", *Urology Practice*, vol. 8, no. 5, pp. 576–582, 2021.

[11] M. R. Cooperberg, Y. Zheng, A. V. Faino, L. F. Newcomb, **K. Zhu**, J. E. Cowan, J. D. Brooks, A. Dash, M. E. Gleave, F. Martin, *et al.*, "Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability", *JAMA oncology*, vol. 6, no. 10, e203187–e203187, 2020.

[12] J. M. Schenk, L. F. Newcomb, Y. Zheng, A. V. Faino, **K. Zhu**, Y. A. Nyame, J. D. Brooks, P. R. Carroll, M. R. Cooperberg, A. Dash, *et al.*, "African american race is not associated with risk of reclassification during active surveillance: Results from the canary prostate cancer active surveillance study", *The Journal of urology*, vol. 203, no. 4, pp. 727–733, 2020.

[13] **K. Zhu**, Y. Huang, and X.-H. Zhou, "Tree-based ensemble methods for individualized treatment rules", *Biostatistics & epidemiology*, vol. 2, no. 1, pp. 61–83, 2018.

[14] K. F. Kerr, J. Roth, **K. Zhu**, H. Thiessen-Philbrook, A. Meisner, F. P. Wilson, S. Coca, and C. R. Parikh, "Evaluating biomarkers for prognostic enrichment of clinical trials", *Clinical Trials*, vol. 14, no. 6, pp. 629–638, 2017.

[15] A. Afzali, C. J. Park, **K. Zhu**, J. K. Hu, P. Sharma, M. N. Sinanan, and S. D. Lee, "Preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease", *Inflammatory Bowel Diseases*, vol. 22, no. 8, pp. 1887–1895, 2016.

[16] K. F. Kerr, M. D. Brown, **K. Zhu**, and H. Janes, "Assessing the clinical impact of risk prediction models with decision curves: Guidance for correct interpretation and appropriate use", *Journal of Clinical Oncology*, vol. 34, no. 21, p. 2534, 2016.

[17] **K. Zhu**, Z. Lou, J. Zhou, N. Ballester, N. Kong, and P. Parikh, "Predicting 30-day hospital readmission with publicly available administrative database", *Methods of information in medicine*, vol. 54, no. 06, pp. 560–567, 2015.

Selected Presentations

- **K. Zhu***, Y. Zhao, and Y. Zheng, "Designing cancer screening trials for the late-stage cancer incidence reduction" ENAR Spring Meeting. Mar. 2024, Baltimore, MD
- **K. Zhu** "Evolving Practices of Results Reporting in ClinicalTrials.gov" Society for Clinical Trials Annual Meeting. May 2019, New Orleans, LA
- **K. Zhu** "Characteristics and Trends of Industry Sponsored Clinical Trials with a DMC – Insights from ClinicalTrials.gov" Society for Clinical Trials Annual Meeting. May 2018, Portland, OR

Professional Services

- **Peer reviewer for:** Contraception and Reproductive Medicine, Biostatistics & Epidemiology, Statistics in Biosciences, Scientific Reports